106 related articles for article (PubMed ID: 26167947)
1. Radionuclide Therapy of Unresectable Tumors with AvidinOX and (90)Y-biotinDOTA: Tongue Cancer Paradigm.
Albertoni C; Leoni B; Rosi A; D'Alessio V; Carollo V; Spagnoli LG; van Echteld C; De Santis R
Cancer Biother Radiopharm; 2015 Sep; 30(7):291-8. PubMed ID: 26167947
[TBL] [Abstract][Full Text] [Related]
2. AvidinOX for highly efficient tissue-pretargeted radionuclide therapy.
De Santis R; Leoni B; Rosi A; Albertoni C; Forni G; Cojoca R; Iezzi M; Musiani P; Paganelli G; Chinol M; Carminati P
Cancer Biother Radiopharm; 2010 Apr; 25(2):143-8. PubMed ID: 20423226
[TBL] [Abstract][Full Text] [Related]
3. Preclinical pharmacology and safety of a novel avidin derivative for tissue-targeted delivery of radiolabelled biotin.
Petronzelli F; Anastasi AM; Pelliccia A; Santapaola D; Albertoni C; Rosi A; Leoni B; Ferrari LE; Paganelli G; Gramiccioli G; Pesce D; Alfano AM; Stasi MA; De Santis R
Basic Clin Pharmacol Toxicol; 2011 Sep; 109(3):145-55. PubMed ID: 21426491
[TBL] [Abstract][Full Text] [Related]
4. Intraoperative avidination for radionuclide therapy: a prospective new development to accelerate radiotherapy in breast cancer.
Paganelli G; Ferrari M; Ravasi L; Cremonesi M; De Cicco C; Galimberti V; Sivolapenko G; Luini A; De Santis R; Travaini LL; Fiorenza M; Chinol M; Papi S; Zanna C; Carminati P; Veronesi U
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5646s-5651s. PubMed ID: 17875802
[TBL] [Abstract][Full Text] [Related]
5. Intraoperative avidination for radionuclide treatment as a radiotherapy boost in breast cancer: results of a phase II study with (90)Y-labeled biotin.
Paganelli G; De Cicco C; Ferrari ME; Carbone G; Pagani G; Leonardi MC; Cremonesi M; Ferrari A; Pacifici M; Di Dia A; De Santis R; Galimberti V; Luini A; Orecchia R; Zurrida S; Veronesi U
Eur J Nucl Med Mol Imaging; 2010 Feb; 37(2):203-11. PubMed ID: 19760414
[TBL] [Abstract][Full Text] [Related]
6. Intraperitoneal pretarget radioimmunotherapy with CC49 fusion protein.
Buchsbaum DJ; Khazaeli MB; Axworthy DB; Schultz J; Chaudhuri TR; Zinn KR; Carpenter M; LoBuglio AF
Clin Cancer Res; 2005 Nov; 11(22):8180-5. PubMed ID: 16299250
[TBL] [Abstract][Full Text] [Related]
7. Growth inhibition of human ovarian carcinoma by a novel AvidinOX-anchored biotinylated camptothecin derivative.
Minenkova O; Vesci L; De Santis R; Santapaola D; Cincinelli R; Musso L; Dallavalle S; Giannini G
Bioorg Med Chem Lett; 2018 Nov; 28(20):3312-3314. PubMed ID: 30243588
[TBL] [Abstract][Full Text] [Related]
8. Intra-tumor AvidinOX allows efficacy of low dose systemic biotinylated Cetuximab in a model of head and neck cancer.
Vesci L; Milazzo FM; Anastasi AM; Petronzelli F; Chiapparino C; Carollo V; Roscilli G; Marra E; Luberto L; Aurisicchio L; Pacello ML; Spagnoli LG; De Santis R
Oncotarget; 2016 Jan; 7(1):914-28. PubMed ID: 26575422
[TBL] [Abstract][Full Text] [Related]
9. In vivo evaluation of pretargeted 64Cu for tumor imaging and therapy.
Lewis MR; Wang M; Axworthy DB; Theodore LJ; Mallet RW; Fritzberg AR; Welch MJ; Anderson CJ
J Nucl Med; 2003 Aug; 44(8):1284-92. PubMed ID: 12902420
[TBL] [Abstract][Full Text] [Related]
10. AvidinOX™ for tissue targeted delivery of biotinylated cells.
Nucera E; Nicoletti C; Chiapparino C; Pacello ML; D'Alessio V; Musarò A; De Santis R
Int J Immunopathol Pharmacol; 2012; 25(1):239-46. PubMed ID: 22507336
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab Radioimmunotherapy (RIT) with Accelerated Blood Clearance Using the Avidin Chase.
Yudistiro R; Hanaoka H; Katsumata N; Yamaguchi A; Tsushima Y
Mol Pharm; 2018 Jun; 15(6):2165-2173. PubMed ID: 29733658
[TBL] [Abstract][Full Text] [Related]
12. IART: intraoperative avidination for radionuclide treatment. A new way of partial breast irradiation.
Paganelli G; Ferrari M; Cremonesi M; De Cicco C; Galimberti V; Luini A; Veronesi P; Fiorenza M; Carminati P; Zanna C; Orecchia R; Veronesi U
Breast; 2007 Feb; 16(1):17-26. PubMed ID: 17174093
[TBL] [Abstract][Full Text] [Related]
13. Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin.
Koppe MJ; Bleichrodt RP; Soede AC; Verhofstad AA; Goldenberg DM; Oyen WJ; Boerman OC
J Nucl Med; 2004 Jul; 45(7):1224-32. PubMed ID: 15235070
[TBL] [Abstract][Full Text] [Related]
14. Comparison of pretargeted and conventional CC49 radioimmunotherapy using 149Pm, 166Ho, and 177Lu.
Mohsin H; Jia F; Bryan JN; Sivaguru G; Cutler CS; Ketring AR; Miller WH; Simón J; Frank RK; Theodore LJ; Axworthy DB; Jurisson SS; Lewis MR
Bioconjug Chem; 2011 Dec; 22(12):2444-52. PubMed ID: 22053899
[TBL] [Abstract][Full Text] [Related]
15. Biological properties of biotin-chelate conjugates for pretargeted diagnosis and therapy with the avidin/biotin system.
Goodwin DA; Meares CF; Osen M
J Nucl Med; 1998 Oct; 39(10):1813-8. PubMed ID: 9776294
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer.
Knox SJ; Goris ML; Tempero M; Weiden PL; Gentner L; Breitz H; Adams GP; Axworthy D; Gaffigan S; Bryan K; Fisher DR; Colcher D; Horak ID; Weiner LM
Clin Cancer Res; 2000 Feb; 6(2):406-14. PubMed ID: 10690517
[TBL] [Abstract][Full Text] [Related]
17. Radioimmunotherapy of A431 xenografted mice with pretargeted B3 antibody-streptavidin and (90)Y-labeled 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA)-biotin.
Yao Z; Zhang M; Axworthy DB; Wong KJ; Garmestani K; Park L; Park CW; Mallett RW; Theodore LJ; Yau EK; Waldmann TA; Brechbiel MW; Paik CH; Pastan I; Carrasquillo JA
Cancer Res; 2002 Oct; 62(20):5755-60. PubMed ID: 12384535
[TBL] [Abstract][Full Text] [Related]
18. Characterization of therapeutic protein AvidinOX by an integrated analytical approach.
Giannini G; Alekseeva A; Naggi A; Salvini L; Tei L; De Santis R
Anal Bioanal Chem; 2018 Jan; 410(2):553-564. PubMed ID: 29167933
[TBL] [Abstract][Full Text] [Related]
19. Pretargeted radioimmunotherapy with a single-chain antibody/streptavidin construct and radiolabeled DOTA-biotin: strategies for reduction of the renal dose.
Förster GJ; Santos EB; Smith-Jones PM; Zanzonico P; Larson SM
J Nucl Med; 2006 Jan; 47(1):140-9. PubMed ID: 16391198
[TBL] [Abstract][Full Text] [Related]
20. Biological comparison of 149Pm-, 166Ho-, and 177Lu-DOTA-biotin pretargeted by CC49 scFv-streptavidin fusion protein in xenograft-bearing nude mice.
Lewis MR; Zhang J; Jia F; Owen NK; Cutler CS; Embree MF; Schultz J; Theodore LJ; Ketring AR; Jurisson SS; Axworthy DB
Nucl Med Biol; 2004 Feb; 31(2):213-23. PubMed ID: 15013487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
